Notes from the Field: Chikungunya Outbreak — Paraguay, 2022–2023
Weekly / June 9, 2023 / 72(23);636–638
Martha Torales1; Amy Beeson, MD2,3; Lorena Grau, MD1; Miguel Galeano, MD1; Andrea Ojeda, Dra.BQ1; Bettiana Martinez1; Nancy León1; Agueda Cabello, MD1; Fátima Rojas1; Viviana de Egea, MD1; Rosa Galeano1; Sandra Ocampos1; Cynthia Vazquez, MPH4; Romeo Montoya, MD5; Susan Hills, MBBS2; Guillermo Sequera, MD1,6 (View author affiliations)
View suggested citationLocal transmission of chikungunya virus (CHIKV) was first reported in the Americas during December 2013, followed by widespread regional transmission (1). CHIKV is transmitted primarily by Aedes aegypti and Aedes albopictus mosquitoes. Most infected persons (72%–97%) experience symptomatic illness, typically including fever and often severe polyarthralgia (which can persist for months or years) (2). Rare complications include neurologic, cardiac, or renal disease (2).
Paraguay reported its first autochthonous chikungunya case during 2015 (3). The subsequent outbreak, concentrated in the capital city of Asunción and the neighboring Central Department, resulted in 5,221 cases during 2015–2016.* A second outbreak (1,239 cases) occurred during 2018 in the north-central Amambay Department. Beginning the first week of October 2022, an increase in reported cases was again noted; this report provides preliminary information on this outbreak as of March 11, 2023.
During October 1, 2022–March 11, 2023, a total of 81,037 suspected, probable, or confirmed† chikungunya cases was recorded by the Paraguayan Ministry of Health§; among these, 75,911 (94%) occurred during 2023. Most cases occurred in Central Department (49,070; 61%) and Asunción (16,094; 20%). Cumulative national incidence was 1,073 cases per 100,000 population (3,088 per 100,000 population in Asunción).¶ Weekly case counts in Asunción and Central Department declined slightly after epidemiologic week 6, but an increasing number and proportion of cases were subsequently reported from outlying regions, including along borders with Brazil and Argentina.
Among 47,116 probable or confirmed cases,** 27,147 (58%) were in females, and the median age was 36 years (range = 0 days–103 years); 4,604 (10%) hospitalizations and 52 (<1%) deaths attributable to CHIKV infection were reported.†† Among 208 (0.4%) cases in infants aged ≤29 days (neonates), 140 hospitalizations and eight deaths were reported,§§ accounting for the highest case fatality rate (3.8%) among all age groups (Figure). Among fatal neonatal cases, the timing of symptom onset suggested intrapartum transmission in 75% and mosquitoborne transmission in 25%.¶¶ Among adults aged ≥60 years, 10,617 cases and 1,878 hospitalizations (41% of all hospitalizations) were reported. Within this group, 32 deaths occurred***; 23 (72%) and 13 (41%) decedents had documented cardiovascular disease and diabetes, respectively, and 20 (63%) had two or more comorbidities. The highest case fatality rate among adults aged ≥60 years occurred among those aged ≥80 years (0.6%; 11 of 1,719 cases).
CHIKV can cause explosive outbreaks and substantial morbidity in all age groups. Groups at risk for severe disease and death include older adults, persons with comorbidities, and infants. Prevention messages should focus on avoiding mosquito bites by wearing long-sleeved shirts and pants, using insect repellents, screening windows and doors, and covering cribs, strollers, and beds with netting. Mosquito breeding sites around homes should be eliminated by emptying, scrubbing, or covering water-holding containers. In addition, integrated vector surveillance and control measures are essential at the community level. Persons with suspected infection should prevent mosquito bites to reduce spread to others. These measures will also reduce the risk for infection from dengue and Zika viruses, which often co-circulate; dengue virus is currently co-circulating in Paraguay.
No antiviral treatment for chikungunya exists; however, timely dissemination of diagnosis and management guidance is crucial.††† Newborns with possible intrapartum exposure should be monitored in a hospital during the first week of life, because deterioration can occur rapidly (4). Infection prevention measures should be implemented in hospitals to limit spread to staff members and patients, including providing bed nets and repellent for inpatients with chikungunya and eliminating mosquito breeding sites from hospital grounds.
Humans are the primary reservoir during epidemics and can transport the virus to new areas; cases in travelers returning from Paraguay have been reported in several countries§§§ (5). If an infected person is bitten by a mosquito vector at their destination, a risk for local transmission exists. During 2022–2023, in the Americas, increases in chikungunya cases and spread outside historical transmission areas (e.g., Uruguay and parts of Argentina) have occurred.¶¶¶ Strengthened surveillance and preparedness are crucial (5). Although no vaccine is currently licensed, several are in the late stages of development and could have a role in reducing cases and deaths in future outbreaks (2).
Acknowledgments
Roberto Jorge Freire Esteves, J. Erin Staples, and staff members of the Paraguayan Ministry of Public Health and Social Welfare.
Corresponding author: Susan Hills, shills@cdc.gov.
1General Directorate of Health Surveillance, Ministry of Public Health and Social Welfare, Asunción, Paraguay; 2Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC; 3Epidemic Intelligence Service, CDC; 4Central Public Health Laboratory, Ministry of Public Health and Social Welfare, Asunción, Paraguay; 5Pan American Health Organization, Asunción, Paraguay; 6Faculty of Medical Sciences, National University of Asunción, Asunción, Paraguay.
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
* https://www.mspbs.gov.py/dependencias/portal/adjunto/0a6e46-SE82023Alerta.pdf
† On the basis of the Paraguayan Ministry of Public Health and Social Welfare’s case definition, a suspected case is illness in a person with abrupt onset of a temperature ≥99.5°F (≥37.5°C) and incapacitating arthralgia or arthritis not explained by another medical condition, or in a neonate with fever, irritability, or cutaneous eruption. A probable case is a clinically compatible case with an epidemiologic link to a confirmed case or a positive CHIKV immunoglobulin (Ig) M test result. A confirmed case is any case with evidence of CHIKV infection determined by reverse transcription–polymerase chain reaction (RT-PCR) testing or virus isolation.
§ The number of suspected cases reported here excludes cases that were discarded on the basis of a negative RT-PCR test result <7 days, or a negative IgM test result ≥7 days, after symptom onset.
¶ Incidence calculated using 2023 population projections from the Paraguayan National Census. https://www.ine.gov.py/microdatos/index.php?cant=99&tema=TODOS
** Probable and confirmed cases were used to describe demographic and clinical findings because data were more complete.
†† Pediatric and adult mortality committees met weekly to review comprehensive clinical information on deaths of patients with probable or confirmed chikungunya and classify the cause of death as attributable to 1) CHIKV infection, or 2) another cause in a patient with concurrent CHIKV infection.
§§ An additional eight deaths of neonates with probable or confirmed chikungunya were determined not attributable to chikungunya, and eight deaths among suspected, probable, or confirmed cases were pending a review of cause of death or laboratory results to confirm infection.
¶¶ Among eight neonates who died, symptom onset after birth was <7 days for six cases and >14 days for two cases.
*** An additional 136 deaths among persons aged ≥60 years with probable or confirmed chikungunya were determined not attributable to chikungunya, and 163 deaths among suspected, probable, or confirmed cases were pending a review of cause of death or laboratory results to confirm infection.
††† https://www.paho.org/en/documents/preparedness-and-response-chikungunya-virus-introduction-americas
References
- Bettis AA, L’Azou Jackson M, Yoon IK, et al. The global epidemiology of chikungunya from 1999 to 2020: a systematic literature review to inform the development and introduction of vaccines. PLoS Negl Trop Dis 2022;16:e0010069. https://doi.org/10.1371/journal.pntd.0010069 PMID:35020717
- de Lima Cavalcanti TYV, Pereira MR, de Paula SO, Franca RFO. A review on chikungunya virus epidemiology, pathogenesis and current vaccine development. Viruses 2022;14:969. https://doi.org/10.3390/v14050969 PMID:35632709
- Gräf T, Vazquez C, Giovanetti M, et al. Epidemiologic history and genetic diversity origins of chikungunya and dengue viruses, Paraguay. Emerg Infect Dis 2021;27:1393–404. https://doi.org/10.3201/eid2705.204244 PMID:33900172
- Gérardin P, Barau G, Michault A, et al. Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the island of La Réunion. PLoS Med 2008;5:e60. https://doi.org/10.1371/journal.pmed.0050060 PMID:18351797
- CDC. Health Alert Network: increased chikungunya virus activity in Paraguay and associated risk to travelers. Atlanta, GA: US Department of Health and Human Services, CDC; 2023. https://emergency.cdc.gov/han/2023/han00487.asp
FIGURE. Number of hospitalizations (N = 4,604) and case fatality rate* among probable and confirmed chikungunya cases, by age group — Paraguay, October 1, 2022–March 11, 2023
* Deaths per 100 cases.
Suggested citation for this article: Torales M, Beeson A, Grau L, et al. Notes from the Field: Chikungunya Outbreak — Paraguay, 2022–2023. MMWR Morb Mortal Wkly Rep 2023;72:636–638. DOI: http://dx.doi.org/10.15585/mmwr.mm7223a5.
MMWR and Morbidity and Mortality Weekly Report are service marks of the U.S. Department of Health and Human Services.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites. URL addresses listed in MMWR were current as of
the date of publication.
All HTML versions of MMWR articles are generated from final proofs through an automated process. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (https://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables.
Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.